arrow_back Trending Legislation
Share share

Nullifying Mifepristone Access Changes: Reverting to Prior Regulations

This bill aims to reverse the January 2023 modifications made by the Food and Drug Administration (FDA) regarding the use of the abortion pill mifepristone. If passed, it would reinstate previous, more restrictive rules for accessing this medication, potentially impacting how citizens obtain it.
Key points
Nullifies FDA's 2023 changes to mifepristone regulations, reverting to previous rules.
Prohibits the Department of Health and Human Services from implementing similar changes in the future.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Print number: HR 679
Sponsor: Rep. Harshbarger, Diana [R-TN-1]
Process start date: 2025-01-23